慶應義塾大学薬学部 統合臨床薬理学講座
当研究室での研究業績
2025年
Atsushi Yonezawa.
Identification and Physiological Analysis of Novel Riboflavin Transporter RFVT
Biol Pharm Bull. 48(7):951-956
Hanyu Y, Kanda J, Sugimoto M, Iwasaki M, Watanabe M, Arai Y, Mizumoto C, Kitawaki T, Yamashita K, Yamagiwa T, Taniguchi R, Nakagawa S, Yonezawa A, Terada T, Takaori-Kondo A.
Effectiveness of posaconazole as primary prophylaxis in allogeneic hematopoietic stem cell transplantation.
Int J Hematol. 2025 Sep 3.
Takashi Masuda, Taro Funakoshi, Takahiro Horimatsu, Sho Masui, Daiki Hira, Marin Inoue, Kodai Yajima, Shunsaku Nakagawa, Yasuaki Ikemi, Junzo Hamanishi, Atsushi Takai, Shinya Yamamoto, Takeshi Matsubara, Masaki Mandai, Hiroshi Seno, Motoko Yanagita, Manabu Muto, Tomohiro Terada, Atsushi Yonezawa.
Population pharmacokinetic analysis of bevacizumab in Japanese cancer patients with proteinuria: a prospective cohort study
Cancer Chemother Pharmacol. 95(1), 46
2024年
Mari Yokoi, Atsushi Yonezawa, Daiki Hira, Tomohiro Handa, Kiminobu Tanizawa, Shunsaku Nakagawa, Masahiro Tsuda, Yasuaki Ikemi, Ryo Itotani, Hironori Yoshida, Motoo Nomura, Junichi Matsubara, Kosaku Murakami, Hiroaki Ozasa, Manabu Muto, Tomohiro Terada.
Subjective symptoms are triggers for the detection of immune checkpoint inhibitor-induced interstitial lung disease and associate with disease severity: a single-center retrospective study
J Pharm Health Care Sci. 10(1), 52
Takahiro Amano, Takeo Yoshihara, Shinichiro Shinzaki, Yuko Sakakibara, Takuya Yamada, Naoto Osugi, Satoshi Hiyama, Yoko Murayama, Koji Nagaike, Hideharu Ogiyama, Toshio Yamaguchi, Yuki Arimoto, Ichizo Kobayashi, Shoichiro Kawai, Satoshi Egawa, Takashi Kizu, Masato Komori, Yuri Tsujii, Akiko Asakura, Taku Tashiro, Mizuki Tani, Yuriko Otake-Kasamoto, Ryotaro Uema, Minoru Kato, Yoshiki Tsujii, Takahiro Inoue, Tomomi Yamada, Tetsuhisa Kitamura, Atsushi Yonezawa, Hideki Iijima, Yoshito Hayashi, Tetsuo Takehara.
Selection of anti-cytokine biologics by pretreatment levels of serum leucine-rich alpha-2 glycoprotein in patients with inflammatory bowel disease
Sci Rep. 14(1), 29755
Tomoya Kawakami, Sho Masui, Akira Onishi, Hideo Onizawa, Takayuki Fujii, Kosaku Murakami, Koichi Murata, Masao Tanaka, Takashi Shimada, Shunsaku Nakagawa, Shuichi Matsuda, Akio Morinobu, Tomohiro Terada, Atsushi Yonezawa.
Comparison of safety and effectiveness between etanercept biosimilar LBEC0101 and reference in patients with rheumatoid arthritis in real-world data using the KURAMA cohort
Mod Rheumatol. 34(6), 1135-1141
Takashi Masuda, Taro Funakoshi, Takahiro Horimatsu, Shinya Yamamoto, Takeshi Matsubara, Sho Masui, Shunsaku Nakagawa, Yasuaki Ikemi, Motoko Yanagita, Manabu Muto, Tomohiro Terada, Atsushi Yonezawa.
Low serum concentrations of bevacizumab and nivolumab owing to excessive urinary loss in patients with proteinuria: a case series
Cancer Chemother Pharmacol. 94(4), 615-622
過去の代表的な研究成果
Sho Masui, Atsushi Yonezawa , Miyuki Nakamura, Akira Onishi, Motomu Hashimoto, Hideo Onizawa, Takayuki Fujii, Kosaku Murakami, Koichi Murata, Masao Tanaka, Kotoko Yokoyama, Noriko Iwamoto, Takashi Shimada, Kotaro Itohara, Daiki Hira, Shunsaku Nakagawa, Satoshi Imai, Takayuki Nakagawa, Makoto Hayakari, Shuichi Matsuda, Akio Morinobu, Tomohiro Terada, Kazuo Matsubara.
Serum Concentrations of Infliximab and IL-6 for Predicting One-Year Discontinuation of Infliximab Treatment Owing to Secondary Non-response in Patients with Rheumatoid Arthritis.
Biol Pharm Bull. 46(8), 1112-1119, 2023.
Sho Masui, Atsushi Yonezawa, Kotoko Yokoyama, Noriko Iwamoto, Takashi Shimada, Akira Onishi, Hideo Onizawa, Takayuki Fujii, Kosaku Murakami, Koichi Murata, Masao Tanaka, Shunsaku Nakagawa, Daiki Hira, Kotaro Itohara, Satoshi Imai, Takayuki Nakagawa, Makoto Hayakari, Shuichi Matsuda, Akio Morinobu, Tomohiro Terada & Kazuo Matsubara.
N-terminus of Etanercept is Proteolytically Processed by Dipeptidyl Peptidase-4.
Pharm Res. 39(10), 2541–2554, 2022.
Sho Masui, Atsushi Yonezawa , Kenji Momo, Shunsaku Nakagawa, Kotaro Itohara, Satoshi Imai, Takayuki Nakagawa, Kazuo Matsubara.
Infliximab Treatment Persistence among Japanese Patients with Chronic Inflammatory Diseases: A Retrospective Japanese Claims Data Study.
Biol Pharm Bull. 45(3), 323-332, 2022.
Kazuto Nakae ,Sho Masui ,Atsushi Yonezawa ,Motomu Hashimoto,Ryu Watanabe,Koichi Murata,Kosaku Murakami,Masao Tanaka,Hiromu Ito,Kotoko Yokoyama,Noriko Iwamoto,Takashi Shimada,Miyuki Nakamura,Masaya Denda,Kotaro Itohara,Shunsaku Nakagawa,Yasuaki Ikemi,Satoshi Imai,Takayuki Nakagawa,Makoto Hayakari,Kazuo Matsubara.
Potential application of measuring serum infliximab levels in rheumatoid arthritis management: A retrospective study based on KURAMA cohort data.
PLoS One. 16(10), e0258601, 2021.
Sho Masui, Atsushi Yonezawa, Kazushi Izawa, Makoto Hayakari, Kayoko Asakura, Risa Taniguchi, Masahiko Isa, Hirofumi Shibata, Takahiro Yasumi, Ryuta Nishikomori, Junko Takita & Kazuo Matsubara.
Plasma infliximab monitoring contributes to optimize Takayasu arteritis treatment: a case report.
J Pharm Health Care Sci. 2019,5(9), 2019.
Atushi Yonezawa, Yuki Otani, Toshiyuki Kitano, Mayuko Mori, Sho Masui, Yui Isomoto, Masahiro Tsuda, Satoshi Imai, Yasuaki Ikemi, Masaya Denda, Yuki Sato, Shunsaku Nakagawa, Tomohiro Omura, Takayuki Nakagawa, Ikuko Yano, Makoto Hayakari, Akifumi Takaori-Kondo & Kazuo Matsubara.
Concentration and Glycoform of Rituximab in Plasma of Patients with B Cell Non-Hodgkin's Lymphoma.
Pharm Res. 36(6), 82, 2019.
Masahiro Tsuda, Yuki Otani, Atsushi Yonezawa , Sho Masui, Yasuaki Ikemi, Masaya Denda, Yuki Sato, Shunsaku Nakagawa, Tomohiro Omura, Satoshi Imai, Takayuki Nakagawa, Makoto Hayakari, Kazuo Matsubara.
Analysis of Glycoforms and Amino Acids in Infliximab and a Biosimilar Product Using New Method with LC/TOF-MS.
Biol Pharm Bull. 41(11), 1716-1721, 2018.